DeCure's autonomous Psychiatry AI scientist is researching a drug-repurposing hypothesis for substance-related disorder — screening already-approved drugs against its 39-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSubstance-related disorder maps to a 39-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for substance-related disorder is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
sorbin and SH3 domain containing 2 (SORBS2) — SORBS2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet unxdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5VEI · 1.33 Å · ligand UNKNOWN ATOM OR ION (UNX). Experimental structure, not a prediction.
What the evidence adds up to
A 2006 review of co-occurring substance use disorders and civilian-related posttraumatic stress disorder found no consensus on best practices. Several integrated psychosocial treatments—Seeking Safety, Substance-Dependence PTSD Therapy, and Concurrent Treatment of PTSD and Cocaine Dependence—showed empirically supported promise in reducing symptoms of both disorders. The review noted that very little research had been conducted on pharmacological treatments for this dual diagnosis or on assessments.
A 2010 review of comorbid conduct disorder and substance use disorders reported that both disorders are heritable, suggesting a common genetic influence. The authors argued that a developmental pathways approach to etiology, correlates, comorbidities, prevention, and treatment may improve understanding. They called for research examining genetic, neurophysiological, behavioural, and environmental connections.
A 2015 paper on high-dose stimulant substitution stated that effective medications have been approved for alcohol, tobacco, and opioid use disorders, but that the biggest gap in pharmacological treatment of addictive disorders is the lack of medications to treat stimulant use disorders such as cocaine and methamphetamine use disorders. Another 2015 paper argued that the term "chronic relapsing disorder/disease" misrepresents treatment accomplishments, citing studies showing that relapse is not inevitable and that substantial reductions in drug use and crime are routinely obtained after treatment.
A 2012 chapter on psychological treatments for substance use disorders listed screening, brief interventions (including the FRAMES method, motivational enhancement therapy, cognitive-behavioral therapy, contingency management, 12-step facilitation, relapse prevention, and treatment of psychiatric conditions) and referral to treatment. What remains missing is a pharmacological option for stimulant use disorders, adequately powered trials for the dual-diagnosis psychosocial treatments, and a consistent framework for patient stratification that accounts for the genetic and developmental pathways described in the conduct disorder review.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Brief Treatment and Crisis Intervention · 2006 · 26 citations
Evidenced-Based Time-Limited Treatment of Co-occurring Substance-Use Disorders and Civilian-Related Posttraumatic Stress Disorder
AbstractSubstance use disorders (SUDs) and posttraumatic stress disorder (PTSD) frequently co-occur, and this comorbidity results in a more severe clinical presentation and treatment outcome. Consensus is lacking regarding best practices; however, a number of integrated psychosocial treatments (e.g., Seeking Safety, Substance-Dependence PTSD Therapy, Concurrent Treatment of PTSD and Cocaine Dependence) have shown empirically supported promise in reducing symptoms of both disorders. Very little research has been conducted to date on pharmacological treatments for this dual diagnosis or on assessments. This article reviews the developing literature in this area and discusses future directions for research.
Clinical Psychology Science and Practice · 2010 · 23 citations
Comorbid conduct disorder and substance use disorders.
Abstract[Clin Psychol Sci Prac 17: 337–349, 2010]
Conduct disorder (CD) and substance use disorders (SUDs) commonly co-occur. The high rates of comorbidity, in conjunction with similar developmental trajectories for CD and SUDs, suggest a common etiology. Both disorders are heritable, indicating a common genetic influence. Research suggests that a developmental pathways approach to the etiology, correlates, comorbidities, prevention, and treatment of CD and SUDs may improve our understanding of these disorders. Research that examines the genetic, neurophysiological, behavioral, and environmental connections among the CD and SUDs is reviewed. Study of the causes of these two disorders, either singly or in combination, is essential to prevent their occurrence and ameliorate the associated negative outcomes.
Japanese Journal of Clinical Oncology · 2015 · 15 citations · open access
Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor
AbstractOBJECTIVE: This study was conducted to expand the sunitinib safety database in Japanese imatinib-resistant/-intolerant gastrointestinal stromal tumor patients. Retrospective analyses investigated common adverse events as potential prognostic markers. METHODS: Four hundred and seventy patients who received sunitinib between June 2008 and November 2009 were analyzed for safety, progression-free survival and overall survival; 386 for objective response rate; 88% received sunitinib on Schedule 4/2 starting at 50 mg/day. RESULTS: No unexpected safety issues occurred. Grade ≥ 3 adverse events occurred in 70%, most commonly thrombocytopenia (33%), neutropenia (22%) and leukopenia (15%). Objective response rate was 20% (95% confidence interval 16-24). Median progression-free survival was 22.4 weeks (95% confidence interval, 21.7-24.0). The overall survival rate at 24 weeks was 91% (95% confidence interval, 88-94). Higher relative dose intensity (≥70 vs. <70%) during the first 6 weeks and better Eastern Cooperative Oncology Group performance status (0 vs. ≥1) were associated with longer progression-free survival (24.0 vs. 20.1 weeks; P = 0.011; and 24.1 vs. 16.9 weeks; P < 0.001) and higher 24-week overall survival rate (94 vs. 83%; P < 0.001; and 96 vs. 83%; P < 0.001). Increased progression-free survival and overall survival rates were associated with specific adverse events. Cox proportional hazard modeling adjusted for relative dose intensity and performance status established hand-foot syndrome (hazard ratio = 0.636; 95% confidence interval, 0.456-0.888) and leukopenia (hazard ratio = 0.683; 95% confidence interval, 0.492-0.948) occurring within 12 weeks were significantly correlated with increased progression-free survival. CONCLUSION: Sunitinib showed good efficacy and tolerable safety. Factors associated with greater efficacy were relative dose intensity, performance status and specific early adverse events.
Journal of Addiction Research & Therapy · 2015 · 2 citations · open access
High Dose Stimulant Substitution for the Treatment of Cocaine and Crystal Meth Use Disorders
AbstractTreatment of substance use disorder has advanced substantially in the last few decades. Psychosocial interventions such as motivational enhancement treatment, CBT for relapse prevention, and contingency management have been developed and are now widely utilized. A number of effective medications have been approved and implemented for the treatment of alcohol, tobacco, and opioid use disorders. The biggest gap, specifically in the pharmacological treatment of addictive disorders, is the lack of medications to treat stimulant use disorders such as cocaine and methamphetamine use disorders.
AbstractThe term "chronic relapsing disorder/disease" is viewed as an unfortunate shorthand expression that does an injustice to the accomplishments of treatment patients and treatment providers, and inadequately describes the findings from treatment evaluation research. Studies are reported that make clear relapse is not an inevitable consequence of substance abuse treatment, while substantial reductions in drug use and crime are routinely obtained consequent to treatment. It is past time to retire a term whose only virtue is brevity, and whose vices risk harm to a treatment population that is already stigmatized and a treatment system that is under frequent pressure. Thus, retiring this term provides the important benefit of recognizing the real achievements in behavior change obtained by treatment clients in conjunction with their service providers.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
